According to a recent LinkedIn post from Cytovale, industry discussion around sepsis diagnostics is shifting from simple test comparisons to evaluating real-world clinical impact. The post references a College of American Pathologists (CAP) Today article and an Association for Diagnostics & Laboratory Medicine (ADLM) presentation that focus on how host response diagnostics perform once implemented in practice.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Cytovale’s IntelliSep sepsis risk assay and emphasizes measures such as clinical outcomes, decision timing, and resource utilization as key benchmarks. Cytovale cites published data suggesting a 42% reduction in mortality among emergency department patients with suspected infection following IntelliSep implementation, alongside more targeted use of blood cultures.
For investors, these reported outcome improvements, if replicated and accepted by clinicians and payers, could support broader adoption of IntelliSep in emergency medicine settings. Expanded clinical use may translate into stronger revenue potential in the sepsis diagnostics market, while demonstrated mortality and efficiency benefits could enhance Cytovale’s competitive positioning among advanced clinical diagnostic platforms.